The Nitrogen Is Bonded Directly To A Carbocyclic Ring Of The Tricyclo Ring System Patents (Class 546/100)
-
Patent number: 11538946Abstract: A sensor module that may include optics and a sensor located downstream to the optics. The optics may include a self-assembling polymer and luminescent elements embedded in the self-assembling polymer.Type: GrantFiled: July 4, 2021Date of Patent: December 27, 2022Assignee: HILLBERRY GAT LTD.Inventors: Viktor Goldovsky, Yonohan Davidovich, David Avner
-
Patent number: 9845390Abstract: Provided are processes for producing fluorescent naphthalimide diesters of Formula (I), useful as fluorescent tracer dyes for fluid system leak detection, wherein each of R1 and R2 is, independently of the other, a saturated, linear hydrocarbon chain having from 2 to 10 carbon atoms; and each of Z1 and Z2 is, independently of the other, a fatty acid moiety having a saturated or unsaturated, linear or branched, hydrocarbon chain having from 8 to 24 carbon atoms, and from 0 to 4 double bonds. Also provided are compositions of the aforesaid diesters of Formula (I).Type: GrantFiled: April 21, 2017Date of Patent: December 19, 2017Assignee: Spectronics CorporationInventor: Daniel Scott Tyson
-
Patent number: 9018377Abstract: The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q+ is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q+.Type: GrantFiled: July 22, 2010Date of Patent: April 28, 2015Assignee: OPTI Medical SystemsInventors: Huarui He, Chao Lin
-
Publication number: 20150079625Abstract: The present invention provides a novel category of naphthalene-based two-photon fluorescent probes having a general formula I, wherein: X is selected from the X1, X2, X3 and X4; The mentioned two-photon fluorescent probes have a low fluorescence background in the non-tumor cells and tissues, and have a strong and specific fluorescent signal in the tumor cells and tissues. These probes have a certain level of water-solubility, while having good membrane permeability. In addition, they have a bigger effective two-photon absorption cross section. The compounds of the present invention also have a lower biotoxicity, phototoxicity and photobleaching. There is sufficient difference between the spectral range thereof and that of a biological sample.Type: ApplicationFiled: March 5, 2012Publication date: March 19, 2015Applicants: DALIAN CHROMAS BIOSCIENCE CO., LTD, DALIAN UNIVERSITY OF TECHNOLOGYInventors: Xiaojun Peng, Hua Zhang, Jiangli Fan, Jingyun Wang
-
Publication number: 20140147876Abstract: The invention relates to devices comprising a sensor layer capable of binding magnesium ions and a scavenging layer that preferentially binds to calcium ions in the presence of both magnesium ions and calcium ions. The sensor layers can comprise known or novel luminionophores. The invention further relates to methods of selectively detecting magnesium ion concentration in the presence of calcium ions.Type: ApplicationFiled: November 29, 2012Publication date: May 29, 2014Applicant: IDEXX Laboratories, Inc.Inventors: Peter Chaoquan ZHU, Yingzi Wu
-
Publication number: 20130131006Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.Type: ApplicationFiled: April 28, 2011Publication date: May 23, 2013Applicant: Gachon University of Industry-Academic Cooperation FoundationInventors: Bong Hee Lee, Kyung Hee Byun
-
Patent number: 8420665Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.Type: GrantFiled: January 12, 2009Date of Patent: April 16, 2013Assignee: Northwestern UniversityInventors: Sui Huang, John Norton, Daniel Appella, Mark Witschl
-
Publication number: 20130074927Abstract: The invention provides highly fluorescent materials comprising a single (n=0) or a series (n=1, 2, etc.) of benzo heterocyclic systems. The photo-stable highly luminescent chromophores are useful in various applications, including in wavelength conversion films. Wavelength conversion films have the potential to significantly enhance the solar harvesting efficiency of photovoltaic or solar cell devices.Type: ApplicationFiled: September 25, 2012Publication date: March 28, 2013Applicant: NITTO DENKO CORPORATIONInventor: NITTO DENKO CORPORATION
-
Publication number: 20130005759Abstract: MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.Type: ApplicationFiled: January 21, 2011Publication date: January 3, 2013Inventors: Alexander Deiters, Douglas D. Young
-
Publication number: 20120329085Abstract: The invention provides reaction-based fluorescent probes for selective imaging of hydrogen sulfide in living cells.Type: ApplicationFiled: June 11, 2012Publication date: December 27, 2012Applicant: The Regents of The University of CaliforniaInventors: Christopher J. CHANG, Alexander R. Lippert, Vivian S. Lin
-
Patent number: 8338603Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.Type: GrantFiled: December 27, 2011Date of Patent: December 25, 2012Assignee: AbbVie Inc.Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
-
Publication number: 20120294808Abstract: A method of imaging using selective fluorescent emitters and compositions for imaging are described. The method can include contacting a specimen with a composition comprising at least one selective fluorescent emitter of Formulas I through IX and irradiating the specimen with an excitation wavelength. The fluorescence emitted by the selective fluorescent emitter can be detected to generate an image. Formulas I through IX are: wherein: R1=OR4 or NR3R4; R2=OR4, NR3R4, Cl, F or H; R3=H, CH3, C2H5, C3H7 or C4H9; R4=H, CH3, C2H5, C3H7 or C4H9; R5=H or CH2(CH2)nNR3R4; R6=H or CH2(CH2)nNR3R4; R7=OR4, NR3R4, Cl, F or H; R8=N-methylpyridinium or N-methyl-1,2,3,6-tetrahydropyridine; and n=1, 2 or 3.Type: ApplicationFiled: November 9, 2010Publication date: November 22, 2012Applicant: UNIVERSITY OF MIAMIInventor: James N. Wilson
-
Publication number: 20120183984Abstract: The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q+ is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q+.Type: ApplicationFiled: July 22, 2010Publication date: July 19, 2012Applicant: OPTI MEDICAL SYSTEMSInventors: Huarui He, Chao Lin
-
Publication number: 20120009683Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.Type: ApplicationFiled: July 29, 2011Publication date: January 12, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kyle Richard GEE, Vladimir MARTIN
-
Publication number: 20110263457Abstract: We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for a detectable characteristic of interest (e.g., presence of an analyte). By employing multiple distinct DCB labels at varying concentrations, one can perform multiplex analyses on up to hundreds or thousands (or more) of cell samples in a single reaction tube. DCB reduces reagent consumption by factors of 100-fold or more, significantly reduces data acquisition times and allows for stringent control sample analysis.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Inventors: Peter O. Krutzik, Garry Nolan
-
Publication number: 20110189096Abstract: To provide a central nervous system tissue-labeling composition labeling the central nervous tissue system. Also, another object of the present invention is to provide a method for non-invasively labeling the central nervous tissue system. Further, another object of the present invention is to provide a screening method using the above central nervous system tissue-labeling composition. A central nervous system tissue-labeling composition containing, as an active ingredient, at least one of compounds represented by the general formula (1) or (7).Type: ApplicationFiled: April 12, 2011Publication date: August 4, 2011Applicant: CANON KABUSHIKI KAISHAInventors: Kohei Watanabe, Taichi Shintou, Tsuyoshi Nomoto, Takeshi Miyazaki, Mie Okano, Toshio Tanaka, Yuhei Nishimura, Yasuhito Shimada
-
Publication number: 20110113572Abstract: The present application relates to a novel family of cationic naphthalimide compounds that can be used as a direct dye, and to a dye composition for the dyeing of keratin fibres, in particular human keratin fibres such as the hair, comprising, in a suitable dyeing medium, at least one such compound. The present application also relates to the dyeing process using this composition and its uses.Type: ApplicationFiled: October 14, 2010Publication date: May 19, 2011Applicant: L' OREAL S.A.Inventors: Tiina Luukas, Andrew Greaves, Hervé David
-
Publication number: 20100303719Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.Type: ApplicationFiled: January 12, 2009Publication date: December 2, 2010Applicant: NORTHWESTERN UNIVERSITYInventors: Sui Huang, John Norton, Daniel Appella, Mark Witschi
-
Patent number: 7803197Abstract: Disclosed are thiol dyes of formula (1) wherein L1 is hydrogen; C1-C12alkyl; or phenyl-C1-C4alkyl; X is C1-C12alkylene, C2-C12alkenylene, C5-C10cycloalkylene, C5-C10arylene, or C5-C10arylene-C1-C10alkylene, which may by interrupted by —O—, —NH—, —S—, —CO—, o-SO2—; Y is the residue of an organic dye Z is a group of formula (1b) or —C?N; wherein A is O; S; or N-L2; B is L3; —OL3; —NL3L4; or —SL3; and L2, L3 and L4, independently from other are hydrogen; C1-C12alkyl; C5-C12aryl-C1-C12alkyl. The compounds are useful for the dyeing of organic materials, such as keratin fibers, preferably human hair.Type: GrantFiled: August 8, 2007Date of Patent: September 28, 2010Assignee: Ciba CorporationInventors: Victor Paul Eliu, Beate Fröhling, Dominique Kauffmann
-
Publication number: 20100168428Abstract: The present invention generally relates to environment-sensitive fluorophores, including environment-sensitive fluorophores for reporting protein/protein and peptide/protein interactions. In one aspect, the present invention is directed to compounds and salts thereof, compositions and methods useful in determining biological interactions. In some cases, the compounds of the present invention are environment-sensitive fluorophores that have spectroscopic behavior that may depend on factors such as the physicochemical properties of the surrounding environment. The compounds of the present invention can be used, in certain embodiments, to monitor ions, small molecules, and biological processes such as protein folding, protein-protein interactions and phosphorylation events.Type: ApplicationFiled: February 26, 2008Publication date: July 1, 2010Applicant: Massachusetts Institute of TechnologyInventors: Barbara Imperiali, Galen S. Loving
-
Publication number: 20090312363Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: ApplicationFiled: February 14, 2007Publication date: December 17, 2009Inventors: James Elliot Bradner, Ralph Mazitschek, Tang Weiping, Stuart S. Schreiber
-
Publication number: 20090215815Abstract: A pharmaceutical composition comprising a compound of Formula I wherein R1 is selected from, inter alia, alkyl, aryl-loweralkyl, heterocycle-loweralkyl, loweralkyl-carbonate; optionally substituted amino; benimidaz-2-yl; optionally substituted phenyl; loweralkyl-(R5)(R6) wherein one of R5 and R6 is selected from H and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl; NHCH2CH2OX wherein X represents an in vivo hydrolyzable ester; and R2 and R3 are independently selected from H, NO2, halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S—, loweralkyl, and Z(O)OR7 wherein Z is selected from C and S and R7 is selected from H, loweralkylamino and arylamino; or pharmaceutically acceptable salts or certain in vivo hydrolyzable esters or amides thereof, in an amount effective to inhibit neurotrophin-mediated activity, and a suitable carrier, is described.Type: ApplicationFiled: April 28, 2009Publication date: August 27, 2009Inventors: Ashok Tehim, Xiannong Chen
-
Publication number: 20090118321Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods for making such derivatives through hydrolysis of known compounds.Type: ApplicationFiled: May 7, 2007Publication date: May 7, 2009Applicant: Unibioscreen S.A.Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van den Hove, Francis Darro, Robert Kiss
-
Publication number: 20090029389Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.Type: ApplicationFiled: July 25, 2008Publication date: January 29, 2009Applicant: INVITROGEN CORPORATIONInventors: Kyle Richard Gee, Vladimir Martin
-
Patent number: 6989390Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X? or R1 is —(CH2)nN+HR3R4 X? or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X?? sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X? is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: October 20, 2003Date of Patent: January 24, 2006Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Patent number: 6890377Abstract: Rylene dyes of the general formula I where R is hydrogen; unsubstituted or substituted C1-C30-alkyl, aryl or hetaryl; R? is unsubstituted or substituted C2-C30-alkyl or C5-C8-cycloalkyl, or substituted methyl; n is 0 or 1, their preparation and use for coloring high-molecular-weight organic and inorganic materials, and aminorylene-3,4-dicarboximide of the formula IV as their intermediates.Type: GrantFiled: February 14, 2002Date of Patent: May 10, 2005Assignees: BASF Aktiengesellschaft, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Arno Böhm, Matthias Krieger, Stefan Becker, Klaus Müllen
-
Patent number: 6768010Abstract: Organophotoreceptors comprise an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: a) a charge transport compound having the formula where R1 and R2 are, independently, hydrogen, an alkyl group, a heterocyclic group, an alkaryl group or an aryl group; X is an aromatic group; Y is an (N,N-disubstituted) arylamine group, such as a (N,N-disubstituted) arylamine group, a carbazole group or a julolidine group; Z is (CH2)m group where m is an integer between 1 and 30 where one or more of the methylene groups is optionally replaced by O, S, C═O, O═C—O, O═C—NR3, sulfoxide, sulfate, phosphate, an aryl group, urethane, urea, a NR4 group, a CHR5 group, or a CR6R7 group where R3, R4, R5, R6, and R7 are, independently, H, hydroxyl, thiol, an amine group, an alkyl group, a heterocyclic group, an alkaryl group, or an aryl group; and E is an epoxy group; and (b) a charge generating coType: GrantFiled: September 16, 2003Date of Patent: July 27, 2004Assignee: Samsung Electronics Co., Ltd.Inventors: Zbigniew Tokarski, Nusrallah Jubran, Vytautas Getautis, Maryte Daskeviciene, Edmundas Montrimas, Valentas Gaidelis
-
Patent number: 6693198Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X− or R1 is —(CH2)nN+HR3R4 X− or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X− sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X− is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: April 22, 2002Date of Patent: February 17, 2004Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Patent number: 6559306Abstract: This invention relates to new fluorescent or non-fluorescent dye compounds having a terminal hydroxy, carboxylic acid/ester or amino group and a process for their preparation. The new fluorescent or non-fluorescent dye compounds are useful as colorants for preparing colored synthetic polymer resins with pigmentary properties, for dyeing or printing homo- or mixed synthetic, semi-synthetic or natural polymers or substrates or for preparing inks. The dye compounds provide excellent properties, especially high temperature stability and easy applicability.Type: GrantFiled: July 13, 2001Date of Patent: May 6, 2003Assignee: Clariant Finance (BVI) LimitedInventors: Bansi Lal Kaul, Jean-Christophe Graciet
-
Patent number: 6486319Abstract: The invention relates to rylene dyes of the general formula (I), wherein the variables have the following meanings: R represents hydrogen; optionally substituted C1-C30 alkyl-C5-C8-cycloalkyl, aryl or hetaryl; R′ represents optionally substituted C2-C30 alkyl or C5-C8 cycloalkyl, substituted methyl; and n is 0 or 1. The invention also relates to the preparation and use of said dyes for coloring highly molecular organic and inorganic materials and to 9-amino-perylene-3,4-dicarboxylic acid imides (Va) as their intermediate products.Type: GrantFiled: February 27, 2002Date of Patent: November 26, 2002Assignees: BASF Aktiengesellschaft, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Arno Böhm, Heinrich Schmeisser, Stefan Becker, Klaus Müllen
-
Patent number: 6410505Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.Type: GrantFiled: June 28, 1999Date of Patent: June 25, 2002Assignee: Microbiomed Corp.Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
-
Patent number: 6358746Abstract: Fluorescent compounds of the formula: wherein R1 and R2 are either both SO3M, or one of R1 and R2 is SO3M and the other is COOM, where M is selected from the group consisting of H, Na, K, Rb, Cs, Li or ammonium, are described and claimed. These inert flurorescent compounds have been found to be resistant to oxidizing biocides. One process for making these compounds is described and claimed as the condensation between a 1,8-naphthalic anhydride possessing the desired functionalities and the appropriately substituted o-phenylene diamine. Alternatively, o-amino-nitro-aromatics may be condensed with the various 1,8-naphthalic anhydrides when the in situ reduction of the nitro group is accomplished with a suitable reducing agent such as iron powder. The resulting fluorescent compounds can be used as inert fluorescent tracers in industrial water systems.Type: GrantFiled: November 8, 1999Date of Patent: March 19, 2002Assignee: Nalco Chemical CompanyInventors: Barbara E. Moriarty, Jerry L. Reddinger
-
Patent number: 6248890Abstract: A fluorescent naphthalimide diester dye that is miscible or soluble in a variety of organic compounds such as, for example, mineral oil, polyalkylene glycols, polyolesters, motor oil, gear oil, synthetic oils, and polyalphaolefins, is provided. The fluorescent naphthalimide diester is useful as a tracer to detect leaks within a fluid systems such as, for example, refrigerant systems, transmission systems, and hydraulic systems. The fluorescent naphthalimide diester dye is comprised of a chromophore having the following structure: wherein: Z and Z′ are the same or different, and are esters attached to saturated or unsaturated linear or branched hydrocarbon chains attached thereto, having from 8 to 24 carbon atoms in length, preferably from 12 to 22 carbon atoms in length, most preferably from 16 to 20 carbon atoms in length, and from 1 to 4 double bonds, most preferably 2 to 3 double bonds.Type: GrantFiled: October 26, 1998Date of Patent: June 19, 2001Assignee: Day-Glo Color Corp.Inventors: Wayne R. Likavec, Thomas C. DiPietro
-
Patent number: 6177570Abstract: Bisimides of the formula I where R1, R2, R3 and R4 have the meanings stated in the description, are prepared in a process in which the corresponding dicarboxylic anhydrides of the formulae II and III R1—CO—O—CO—R2 (II) R3—CO—O—CO—R4 (III), are reacted with an amine of the formula H2N—R—NH2 in the presence of a tertiary amine.Type: GrantFiled: September 14, 1999Date of Patent: January 23, 2001Assignee: BASF AktiengesellschaftInventors: Wolfgang Viergutz, Stefan Koser
-
Patent number: 6150306Abstract: A dye composition has the formula: ##STR1## where R.sup.1 and R.sup.2 are the same or different and are selected from (A) C.sub.2 -C.sub.12 alkyloxyalkyl, and (B) C.sub.9-12 alkyl, (A) comprising from about 30 to 80 mole % of the R groups, (B) comprising 20 to about 70 mole % of the R groups. The dye composition is useful as a fluorescent tracer in refrigerant lubricants of the polyol ester types used in non-Freon refrigerants.Type: GrantFiled: March 4, 1999Date of Patent: November 21, 2000Assignee: Morton Internatioanl Inc.Inventor: Michael R. Friswell
-
Patent number: 6133259Abstract: Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.Type: GrantFiled: November 9, 1998Date of Patent: October 17, 2000Assignee: University of PittsburghInventors: William E. Klunk, Jay W. Pettegrew, Chester A. Mathis, Jr.
-
Patent number: 5998621Abstract: This invention relates to colorants comprising naphthalimide base groups with specific water-solubilizing pendant moieties attached. These pendant moieties are based upon aryloxypolyoxyalkylene groups which provide the desired solubility to the naphthalimide colorant compound. Furthermore, the aryloxypolyoxyalkylene groups facilitate the further addition of other pendant groups to the base compound which increase or decrease the solubility of the resultant naphthalimide derivative colorant as well. Such modified naphthalimides are useful as fluorescent colorants, particularly within other liquid media (both aqueous and non-aqueous) without the necessary inclusion of surfactants, solvents, diluents, and the like. Methods of making such colorants, as well as the aryloxypolyoxyallylene intermediates, are also contemplated within this invention.Type: GrantFiled: February 2, 1999Date of Patent: December 7, 1999Assignee: Milliken & CompanyInventor: Robert L. Mahaffey, Jr.
-
Patent number: 5981753Abstract: Disclosed herein are compounds pharmaceutical compositions containing same of the formula1. A compound of the Formula ##STR1## wherein X, X', X" and X'", A, B, D, R, and R' are as identified in the specification and their preparation. Pharmaceutical compositions containing same can be used in the treatment of cancer.Type: GrantFiled: July 15, 1997Date of Patent: November 9, 1999Assignee: BASF AktiengesellschaftInventors: Gerhard Keilhauer, Cynthia Romerdahl, Miguel Fernandez Brana, Xiao-Dong Qian, Peter Bousquet, Jose Maria Castellano Berlanga, Marina Moran Moset, Maria Jesus Perez De Vega
-
Naphthalimide colorants with improved compatibility in refrigeration and air conditioning lubricants
Patent number: 5918269Abstract: Novel naphthalimide-derivative colorants are provided which are present in a neat liquid state at ambient temperature and pressure. Such colorants are produced through the reaction between 4-chloro (or bromo)-1,8 naphthalic anhydride and at least one etheramine, at least one branched alkylamine, or mixtures thereof. The inventive colorants are excellent leak detection agents for refrigeration and air conditioning systems. These naphthalimide derivatives are completely miscible in all different types of standard refrigeration and air conditioning lubricants. Furthermore, since these colorants are liquid, they are not susceptible to crystallizing within such systems. Thus, the inventive naphthalimide leak detecting agents cannot cause the failure of such machinery due to the crystallization of colorant and subsequent clogging of system compressors. Methods of making and using such inventive naphthalimide-derivative colorants are also disclosed.Type: GrantFiled: February 18, 1998Date of Patent: June 29, 1999Assignee: Milliken & CompanyInventor: Robert L. Mahaffey, Jr. -
Patent number: 5917045Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.Type: GrantFiled: June 7, 1995Date of Patent: June 29, 1999Assignee: MicroBioMed CorporationInventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
-
Patent number: 5858930Abstract: 1,8-Naphthalimide derivatives of Formula (I) are useful as fluorescent dyes: ##STR1## wherein R.sup.1 and R.sup.2 are each independently selected from the group consisting of branched alkyl groups containing 7-8 carbon atoms and alkyloxyalkyl groups containing 4 to 24 carbon atoms.Type: GrantFiled: May 30, 1997Date of Patent: January 12, 1999Assignee: United Color Manufacturing, Inc.Inventors: Bharat Desai, Michael J. Smith
-
Patent number: 5840903Abstract: This invention relates to compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof wherein Z is selected from the group consisting of ##STR2## R.sub.1 is alkoxy of one to six carbon atoms; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and are selected from the group consisting of hydrogen, halogen, CF.sub.3, hydroxy, alkoxy of one to six carbon atoms, acyl of two to seven carbon atoms, amino, amino substituted by one or two alkyl groups of one to six carbon atoms, C.sub.2 -C.sub.7 acylamino, aminocarbonyl, aminosulfone optionally substituted by one or two alkyl groups of one to six carbon atoms, C.sub.1 -C.sub.6 alkylsulfone and nitro;m is 1 or 2;X is O or NR.sub.7 ; andR.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms.Type: GrantFiled: July 27, 1992Date of Patent: November 24, 1998Assignee: G. D. Searle & Co.Inventors: Daniel Lee Flynn, Robert L. Shone
-
Patent number: 5817820Abstract: The present invention relates to optical isomers of quinoline compounds of Formula (IA) or Formula (IA'), their pharmaceutically acceptable salts and their intermediates: ##STR1## In the above formulae, A represent nitrogen or ##STR2## in which Y represents hydrogen, halogen such as fluorine or chlorine, lower alkyl or lower alkoxy such as methoxy, or together with R.sub.1 forms --CH.sub.2 CH.sub.2 CH.sub.2 --, CH.sub.2 CH.sub.2 CH(CH.sub.3)--, --OCH.sub.2 CH.sub.2 --, --OCH.sub.2 CH(CH.sub.3)--, --SCH.sub.2 CH.sub.2 -- or --SCH.sub.2 CH(CH.sub.3)--; R.sub.1 is as defined above or represents straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms, a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms which is substituted with a halogen atom, a phenyl group or a phenyl group substituted with one or two halogen atoms, such as ethyl, cyclopropyl or 2,4-difluorophenyl; R.sub.Type: GrantFiled: July 20, 1994Date of Patent: October 6, 1998Assignee: Korea Research Institute of Chemical TechnologyInventors: Wan Joo Kim, Tae Ho Park, Moon Hwan Kim, Jewn Giew Park, Bong Jin Kim
-
Patent number: 5663449Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: June 6, 1995Date of Patent: September 2, 1997Assignee: Hoechst Marion Roussel, Inc.Inventor: Joseph T. Strupczewski
-
Patent number: 5658911Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: September 20, 1994Date of Patent: August 19, 1997Assignee: Hoechst Marion Roussel, Inc.Inventors: Joseph T. Strupczewski, Kenneth J. Bordeau, Edward J. Glamkowski, Yulin Chiang, Grover C. Helsley
-
Patent number: 5654319Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignee: Hoechst Marion Roussel, Inc.Inventors: Edward J. Glamkowski, Yulin Chiang
-
Patent number: 5641782Abstract: This invention relates to 3-Pyrimidinyl Bisnaphthalimides as Anticancer Agents and pharmaceutically acceptable salts thereof, of the formula: ##STR1## and processes for the preparation of such compounds, pharmaceutical composition containing such compounds, and methods of using such compounds to treat cancer, particularly solid tumor carcinomas, in mammals.Type: GrantFiled: February 16, 1995Date of Patent: June 24, 1997Assignee: The DuPont Merck Pharmaceutical CompanyInventors: Jung-Hui Sun, Steven P. Seitz
-
Patent number: 5639764Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents, the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: June 6, 1995Date of Patent: June 17, 1997Assignee: Hoechst-Marion-Roussel, Inc.Inventors: Edward J. Glamkowski, Yulin Chiang
-
Patent number: RE37729Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: February 3, 1999Date of Patent: June 4, 2002Assignee: Aventis Pharmaceuticals Inc.Inventors: Edward J. Glamkowski, Yulin Chiang, Joseph T. Strupczewski, Kenneth J. Bordeau, Peter A. Nemoto, John J. Tegeler
-
Patent number: RE39265Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: November 9, 2000Date of Patent: September 5, 2006Assignee: Aventis Pharmaceuticals Inc.Inventors: Joseph T. Strupczewski, Kenneth J. Bordeau, Edward J. Glamkowski, Yulin Chiang, Grover C. Helsley